Sameer Urgaonkar
Broad Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sameer Urgaonkar.
Journal of Medicinal Chemistry | 2009
Vishal Patel; Ralph Mazitschek; Bradley I. Coleman; Cokey Nguyen; Sameer Urgaonkar; Joseph F. Cortese; Robert Barker; Edward Greenberg; Weiping Tang; James Elliot Bradner; Stuart L. Schreiber; Manoj T. Duraisingh; Dyann F. Wirth; Jon Clardy
A library of approximately 2000 small molecules biased toward inhibition of histone deacetylases was assayed for antimalarial activity in a high-throughput P. falciparum viability assay. Active compounds were cross-analyzed for induction of histone hyperacetylation in a human myeloma cell line to identify HDAC inhibitors with selectivity for P. falciparum over the human host. To verify on-target selectivity, pfHDAC-1 was expressed and purified and a biochemical assay for pfHDAC-1 activity was established.
Chemistry & Biology | 2011
Carolyn K. Dong; Sameer Urgaonkar; Joseph F. Cortese; Francisco-Javier Gamo; Jose Garcia-Bustos; Maria Jose Lafuente; Vishal Patel; Leila Ross; Bradley I. Coleman; Emily R. Derbyshire; Clary B. Clish; Adelfa E. Serrano; Mandy Cromwell; Robert Barker; Jeffrey D. Dvorin; Manoj T. Duraisingh; Dyann F. Wirth; Jon Clardy; Ralph Mazitschek
Here we report the discovery of tetracyclic benzothiazepines (BTZs) as highly potent and selective antimalarials along with the identification of the Plasmodium falciparum cytochrome bc(1) complex as the primary functional target of this novel compound class. Investigation of the structure activity relationship within this previously unexplored chemical scaffold has yielded inhibitors with low nanomolar activity. A combined approach employing genetically modified parasites, biochemical profiling, and resistance selection validated inhibition of cytochrome bc(1) activity, an essential component of the parasite respiratory chain and target of the widely used antimalarial drug atovaquone, as the mode of action of this novel compound class. Resistance to atovaquone is eroding the efficacy of this widely used antimalarial drug. Intriguingly, BTZ-based inhibitors retain activity against atovaquone resistant parasites, suggesting this chemical class may provide an alternative to atovaquone in combination therapy.
Organic Letters | 2010
Sameer Urgaonkar; Joseph F. Cortese; Robert Barker; Mandy Cromwell; Adelfa E. Serrano; Dyann F. Wirth; Jon Clardy; Ralph Mazitschek
The development of a concise strategy to access 2-amino-3-hydroxy-indoles, which are disclosed as novel antimalarials with potent in vivo activity, is reported. Starting from isatins the target compounds are synthesized in 2 steps and in good yields via oxoindole intermediates by employing tert-butyldimethylsilyl amine (TBDMSNH(2)) as previously unexplored ammonia equivalent.
Organic Letters | 2005
Sameer Urgaonkar; Henry S. La Pierre; Israel Meir; Henrik Lund; Debabrata RayChaudhuri; Jared T. Shaw
Angewandte Chemie | 2011
Young Sam Park; Charles I. Grove; Marcos González-López; Sameer Urgaonkar; James C. Fettinger; Jared T. Shaw
Journal of Organic Chemistry | 2007
Sameer Urgaonkar; Jared T. Shaw
Bioorganic & Medicinal Chemistry Letters | 2007
Shubhasish Mukherjee; Carolyn A. Robinson; Andrew G. Howe; Tali Mazor; Peter A. Wood; Sameer Urgaonkar; Alan M. Hebert; Debabrata RayChaudhuri; Jared T. Shaw
e-EROS Encyclopedia of Reagents for Organic Synthesis | 2006
Ann Coates Lescher Savoca; Sameer Urgaonkar
Speciality chemicals | 2006
Sameer Urgaonkar; John G. Verkade
Synfacts | 2011
Young Sam Park; Charles I. Grove; Marcos González-López; Sameer Urgaonkar; James C. Fettinger; Jared T. Shaw